Caribou Biosciences Soars Over 120% - What's Driving The Rally?

(RTTNews) - Shares of Caribou Biosciences Inc. (CRBU) are up over 120% at $5.51 in premarket trading on Monday, as the company gears up to report a slew of clinical trial data during a webcast at 8:00 a.m. ET today.

The company will report new data from its ANTLER Phase 1 trial evaluating vispacabtagene regedleucel (vispa-cel), an allogeneic anti-CD19 CAR-T therapy for patients with relapsed or refractory B-cell non-Hodgkin lymphoma (r/r B-NHL).

Caribou will also share first-in-human results from its phase 1 trial for CB-011, an allogeneic anti-BCMA CAR-T therapy targeting relapsed or refractory multiple myeloma, dubbed CaMMouflage, along with details on its anticipated pivotal phase 3 trial design for vispa-cel and next steps in advancing CB-011.

CRBU has traded in a range of $0.66 to $3.00 in the last 1 year. The stock closed Friday's trading at $2.42, up 4.31%.